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Mixed-lineage leukemia (MLL) fusions are potent oncogenes that
initiate aggressive forms of acute leukemia. As aberrant tran-
scriptional regulators, MLL-fusion proteins alter gene expression
in hematopoietic cells through interactions with the histone H3
lysine 79 (H3K79) methyltransferase DOT1L. Notably, interference
with MLL-fusion cofactors like DOT1L is an emerging therapeutic
strategy in this disease. Here, we identify the histone H2B E3 ubiq-
uitin ligase ring ﬁnger protein 20 (RNF20) as an additional chromatin
regulator that is necessary for MLL-fusion–mediated leukemo-
genesis. Suppressing the expression of Rnf20 in diverse models
of MLL-rearranged leukemia leads to inhibition of cell proliferation,
under tissue culture conditions as well as in vivo. Rnf20 knockdown
leads to reduced expression of MLL-fusion target genes, effects re-
sembling Dot1l inhibition. Using ChIP-seq, we found that H2B
ubiquitination is enriched in the body of MLL-fusion target genes,
correlating with sites of H3K79 methylation and transcription elon-
gation. Furthermore, Rnf20 is required to maintain local levels of
H3K79 methylation by Dot1l at Hoxa9 and Meis1. These ﬁndings
support a model whereby cotranscriptional recruitment of Rnf20 at
MLL-fusion target genes leads to ampliﬁcation of Dot1l-mediated
H3K79 methylation, thereby rendering leukemia cells dependent
on Rnf20 to maintain their oncogenic transcriptional program.
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The mixed-lineage leukemia (MLL) protooncogene (also calledMLL1) was ﬁrst cloned based on its involvement in chromo-
somal translocations found in leukemia, occurring at a frequency
of 5–10% in acute myeloid leukemia (AML) and acute lympho-
blastic leukemia (1).MLL translocations are especially common in
infant acute leukemias and in secondary AMLs that arise follow-
ing cancer treatment with topoisomerase II inhibitors (1). In both
of these clinical settings,MLL rearrangements are associated with
a poor outcome (1). MLL-rearranged leukemias are notable for
(i) a paucity of additional gene mutations found in these cases
(although NRAS mutations are among the most common coop-
erating lesion) (2), (ii) a unique transcriptional signature char-
acterized by overexpression of homeobox A (HOXA) genes (1),
and (iii) an absence of available targeted therapies. Regarding
the latter, the current clinical management of MLL-rearranged
leukemia with cytotoxic chemotherapy is similar to that of other
genetic subtypes of leukemia that fall into the same risk category
(1). Hence, a strong rationale exists to deﬁne unique therapeutic
targets tailored to the molecular pathogenesis of this disease.
MLL encodes a chromatin regulator belonging to the SET1
family of histone H3K4 methyltransferases, which form multi-
subunit protein complexes that maintain active transcription (1,
3). MLL translocations found in leukemia generate fusions that
encode an N-terminal fragment of MLL (which lacks the meth-
yltransferase domain) linked to a C-terminal fragment of various
partner proteins (1). This N-terminal fragment of MLL physically
interacts with Menin, CpG-rich DNA, and the polymerase
associated factor (PAF) complex, which collectively are sufﬁ-
cient for chromatin occupancy at speciﬁc genes such as HOXA9
(4–6). The translocation partners of MLL can be highly diverse;
however, fusions with AF9 are the most common in AML (1).
The aberrant recruitment of AF9-associated proteins to MLL-
occupied genes (e.g., HOXA9) leads to transcriptional deregu-
lation and, consequently, leukemia initiation. Several binding
partners of AF9 are involved in MLL-AF9–mediated leukemo-
genesis, including the super elongation complex (SEC), the
histone H3K79 methyltransferase DOT1L, and the chromodo-
main-containing protein CBX8 (7–10).
Targeting of MLL-fusion–associated factors has emerged as a
promising therapeutic strategy in this subtype of leukemia. Ge-
netic studies have validated that conditional inactivation Dot1l
speciﬁcally inhibits progression of MLL-rearranged leukemias in
vivo, in association with reduced expression of MLL-AF9 target
genes (11, 12). Furthermore, a small-molecule inhibitor of DOT1L
demonstrates antileukemia activity in MLL-rearranged disease
models (13). Genetic or pharmacological disruption of the MLL:
Menin interaction has also been validated as means of sup-
pressing proliferation of MLL-fusion leukemias (5, 14). Target-
ing of DOT1L or Menin in cells that lack MLL rearrangements
leads to remarkably little toxicity, suggesting a potential thera-
peutic window for this general approach (13, 14).
Ring ﬁnger protein 20 (Rnf20) (also called Bre1a) is the major
H2B-speciﬁc ubiquitin ligase in mammalian cells that targets
lysine 120 for monoubiquitination [H2B ubiquitination (H2Bub)]
(15–18). Rnf20 can be recruited to chromatin via the PAF com-
plex, resulting in the accumulation of H2Bub at genes in a tran-
scription-dependent manner (19–22). Although found broadly
at active genes, H2Bub is not strictly required for transcription
elongation, but instead performs specialized roles in regulating
nucleosome dynamics (22), the DNA damage response (23, 24),
and the activity of other histone-modifying enzymes (19, 21,
22). Regarding the latter, it is known that the presence of H2Bub
on nucleosomes can stimulate the activity of DOT1L in cata-
lyzing H3K79 methylation in vitro and in vivo through apparent
allosteric regulation (19, 25). H2Bub also promotes H3K4
methylation by the SET1 family of lysine methyltransferases (26).
The role of H2Bub in supporting histone methylation in mam-
malian cells appears to be dependent on the speciﬁc cell type
and/or on the speciﬁc genomic region examined (17, 27, 28).
Although substantial evidence indicates cross talk between
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H2Bub and H3K79 methylation in various contexts, it has yet to
be addressed whether mammalian Rnf20 supports the bi-
ological functions performed by Dot1l in vivo.
Here, we identify a role for Rnf20 in the pathogenesis of
MLL-fusion leukemia. Suppression of Rnf20 leads to impaired
leukemia progression in vivo associated with reduced expres-
sion of MLL-AF9 target genes, a ﬁnding we link to a defect in
maintenance of local H3K79 methylation. Hence, our ﬁndings
implicate Rnf20 as a key requirement for MLL-fusion leukemia
through regulatory cross talk with Dot1l.
Results
Rnf20 Is Required for Proliferation of MLL-Fusion Leukemia Cells.
Based on the known role of H2Bub in stimulating H3K79 meth-
ylation in various systems (19, 25, 29), we hypothesized that Rnf20
might support the leukemogenic function of Dot1l in MLL-rear-
ranged disease. We approached this question in a systematic
fashion in which we suppressed expression of several histone
monoubiquitination regulators and evaluated the impact on pro-
liferation of MLL-fusion+ leukemia cells. We constructed a set of
45 shRNA vectors targeting the known E2 conjugating enzymes,
E3 ligases, and deubiquitinating enzymes with speciﬁcity for his-
tone H2A or H2B for monoubiquitination (13 genes in total) (30).
Each shRNA (linked to a GFP reporter) was retrovirally in-
troduced into cells derived from a genetically engineered mouse
model of MLL-AF9/NrasG12D AML, shown previously to reca-
pitulate an aggressive, chemotherapy-resistant disease subtype
(31). The GFP positivity of partially infected cells was tracked
by ﬂow cytometry over 8 d to monitor the relative rate of accu-
mulation of shRNA+/GFP+ cells relative to shRNA−/GFP−
cells. Four shRNAs targeting Rnf20 were found to inhibit leu-
kemia proliferation/viability compared with a negative control
shRNA targeting Renilla luciferase and a positive control shRNA
targeting the replication protein A3 (Rpa3) (Fig. 1A) (32). No-
tably, all of the other shRNAs targeting ubiquitination regulators
led to negligible effects on leukemia proliferation (Fig. 1A). This
includes shRNAs targeting Ube2a and Ube2b, which encode
Rad6a and Rad6b, respectively, the E2-conjugating enzymes that
work in conjunction with Rnf20 to catalyze H2Bub (21). Prior
studies suggest that Rad6a and Rad6b function redundantly to
maintain H2Bub in mammalian cells (21), which may explain
why these shRNAs individually failed to evoke a phenotype in the
screen. Based on these results, we focused our subsequent eval-
uation on Rnf20 as a unique chromatin regulator requirement in
MLL-rearranged leukemia.
To determine whether the observed phenotypes represent
on-target consequences of Rnf20 knockdown, we cloned three
additional shRNAs and analyzed the correlation between knock-
down potency and growth inhibition (Fig. 1B). Among the seven
Rnf20 shRNAs evaluated, the knockdown efﬁciency correlated
closely with the degree of proliferation inhibition, consistent
with on-target effects (Fig. 1B). Knockdown of Rnf20 led to
G1 arrest of leukemia cells (using a BrdU incorporation assay),
without evidence of myeloid maturation (Fig. S1). Notably,
Rnf20 suppression led to only minimal antiproliferative effects in
immortalized ﬁbroblasts (Fig. 1C) and in nontransformed hema-
topoietic cell lines 32D, EML, and G1E (Fig. S2A). Rnf20
shRNAs also showed minimal effects on proliferation of vari-
ous epithelial cancer cell lines (Fig. S2 B and C). Furthermore,
RNF20 knockdown inhibited the proliferation of human AML
lines harboring MLL translocations (MOLM-13, MV4-11, and
THP-1), whereas the non–MLL-rearranged AML line CMK
was affected to a lesser extent (Fig. 1D and Fig. S3). MOLM-13
and THP-1 cells harbor MLL-AF9, whereas MV4-11 harbors an
MLL-AF4 translocation, suggesting that RNF20 is required for
proliferation in the setting of different MLL-fusion partners.
Together, these results suggest that Rnf20 is required for pro-
liferation of MLL-fusion leukemias in vitro.
We next considered whether Rnf20 was required for leukemia
proliferation in vivo. For this purpose, we used a Tet-On+/Lu-
ciferase+MLL-AF9/NrasG12D leukemia line, called RN2 (33).
RN2 cells were retrovirally transduced with Rnf20 or control
shRNAs in the TRMPV-Neo vector, which links expression of
a doxycycline (dox)-inducible shRNA to a dsRed reporter (33).
Following neomycin selection, we derived clonal lines by limiting
dilution (Fig. S4A). These lines were then transplanted into sub-
lethally irradiated recipient mice followed by dox administration
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Fig. 1. Rnf20 is required for proliferation of MLL-AF9/NrasG12D leukemia
cells in vitro. (A) shRNA screen of histone monoubiquitination regulators
evaluating for effects on expansion of MLL-AF9/NrasG12D acute myeloid
leukemia cells. Each horizontal bar represents an individual LMN-shRNA
targeting the indicated gene. The fold decrease in GFP-positive cells be-
tween day 2 and day 8 was used to infer the competitive disadvantage of
shRNA+/GFP+ cells relative to untransduced cells in each culture. The dashed
line indicates an arbitrary twofold cutoff. shRNAs targeting Rpa3 and Renilla
luciferase are included as positive and negative controls, respectively. (B)
Correlation between degree of Rnf20 knockdown and degree of proliferation
inhibition for seven independent shRNAs. The percentage of shRNA/GFP-
positive leukemia cells at the indicated time points is shown in the upper
panel, normalized to day 2. Mean of three independent experiments is
shown. In the lower panel, Western blotting of whole-cell extracts prepared
from G418-selected immortalized mouse embryonic ﬁbroblasts transduced
with the indicated LMN shRNAs. β-Actin is included as a loading control.
Representative experiment of three independent repeats is shown. (C )
Impact of Rnf20 shRNAs on proliferation of immortalized mouse embryonic
ﬁbroblasts. The percentage of shRNA+/GFP+ cells at the indicated time points
is shown, normalized to day 2. (D) Impact of a RNF20 shRNA on proliferation
of human AML cell lines. The percentage of shRNA+/GFP+ cells at the in-
dicated time points is shown, normalized to day 4. Mean of three in-
dependent experiments is shown. All error bars denote SEM.
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after 5–6 d, when the disease is engrafted and actively expanding.
We found that two independent Rnf20 shRNAs inhibited leu-
kemia progression, as indicated by a decreased rate of bio-
luminescent signal accumulation (Fig. 2 A and B, and Fig. S4 B
and C) and an extension in overall survival compared with
controls (Fig. 2C). The terminal disease of leukemias expe-
riencing Rnf20 knockdown exhibited a reduced percentage of
dsRed positivity compared with the pretransplanted clone
(Fig. S4A). This suggests that subclones that have bypassed Rnf20
shRNA expression emerge in vivo under the negative-selection
pressure imposed by Rnf20 suppression. These ﬁndings conﬁrm
that Rnf20 is necessary for rapid leukemia expansion under in
vivo conditions.
Rnf20 Is Required to Maintain Expression of MLL-AF9 Target Genes.
To gain mechanistic insight into the role of Rnf20 in MLL-fusion
leukemia, we performed global gene expression proﬁling. Two
independent shRNAs targeting Rnf20 were induced in RN2 cells
with dox for 4 d followed by RNA sequencing analysis. We ranked
all expressed genes based on their fold change in mRNA level
following Rnf20 suppression, which, importantly, validated Rnf20
itself as among the most down-regulated genes (Fig. 3A). This
further supports the on-target effects of the shRNAs used here.
Inspection of the other affected genes revealed that many of the
known direct MLL-AF9 target genes [homeobox A9 (Hoxa9),
homeobox A10 (Hoxa10), Meis homeobox 1 (Meis1), and myo-
cyte enhancer factor 2C (Mef2c)] were also among the most
down-regulated (Fig. 3A). Interestingly, these changes in ex-
pression were unique to Rnf20 suppression, as inhibiting
other chromatin regulators (BRD4 or PRC2) in this same
leukemia model fails to inﬂuence expression of this set of genes
(Fig. S5) (34). Using gene set enrichment analysis (GSEA), we
further veriﬁed a systematic suppression of MLL-AF9 target
gene expression upon Rnf20 knockdown (35). We also noted
a pronounced decrease in the expression of Dot1l-dependent
genes (Fig. 3C), using a gene set deﬁned previously in a Dot1l−/−;
MLL-AF9 leukemia model (11). Together, these data highlight
a signiﬁcant overlap between the genes up-regulated by Rnf20
and those up-regulated by MLL-AF9/Dot1l.
Upon Rnf20 knockdown, we also noted a paradoxical up-
regulation of Myc expression and associated leukemia stem cell
gene signatures (Fig. S6) (36). This unexpected result may ex-
plain the lack of myeloid maturation observed following Rnf20
suppression, as Myc levels are known to play a role in regulating
the differentiation program in this disease (37). Prior studies also
found that RNF20 can repress MYC expression in HeLa cells
(27) but, conversely, can also promote MYC expression in LNCaP
cells (38). These data would suggest that Rnf20 inﬂuences Myc
expression in nonleukemia cellular contexts, albeit in either a pos-
itive or a negative manner depending on cell type. Nevertheless,
Rnf20 inhibition leads to a unique situation in leukemia where
G1 arrest occurs despite increased levels of Myc expression.
RNF20 has been found previously to play a role in the DNA
damage response, with RNF20-deﬁcient HeLa cells being more
sensitive to DNA-damaging agents (23, 24). Interestingly, we
failed to observe increased sensitivity of RNF20-deﬁcient leuke-
mia cells to cytotoxic agents etoposide or daunorubicin (Fig. S7).
In contrast, we found that RNF20-deﬁcient leukemia cells are
hypersensitive to the BRD4 inhibitor JQ1, which exerts its effects
in part through lowering of MYC expression in AML (37). The
observed antileukemia effects when combining BRD4 and RNF20
inhibition might be related to the paradoxical MYC up-regulation
that occurs in RNF20-deﬁcient leukemia cells as described above
(Fig. S6). These results further highlight a unique, context-speciﬁc
role for RNF20 in AML.
H2B Ubiquitination Is Enriched in the Transcribed Region of MLL-AF9
Target Genes.We next used ChIP-seq to evaluate whether Rnf20
and H2Bub might play direct roles in regulating transcription of
MLL-AF9 target genes. Our attempts at immunoprecipitating
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Fig. 3. Knockdown of Rnf20 leads to decreased expression of MLL-AF9/
Dot1l target genes. (A) RNA-seq data heat map indicating fold change in
gene expression comparing shRen.713 to two independent Rnf20 shRNAs
(3,595 and 3,277) after 4 d of dox induction. An expression cutoff (RPKM >
20) was implemented. (B and C) GSEA plots evaluating changes in MLL-AF9
targets and Dot1l-dependent gene signatures upon Rnf20 knockdown. FDR
q-val, false discovery rate q-value (the probability that a gene set with a
given normalized enrichment score represents a false-positive ﬁnding); NES,
normalized enrichment score.
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Rnf20 were unsuccessful, so as an alternative we used an H2Bub-
speciﬁc antibody since Rnf20 is the major E3 ligase catalyzing
this modiﬁcation in mammalian cells (21, 27). For these ChIP-seq
experiments, we evaluated H2Bub, H3K79me2, and H3K4me3
in the human AML cell line THP-1, which harbors an endoge-
nous MLL-AF9 translocation. Using this approach, we identiﬁed
a broad enrichment of H2Bub at the HOXA cluster that reached
its highest levels within the gene bodies, a localization pattern
that resembled that of H3K79me2 (Fig. 4A). We also found
H3K4me3 to be enriched in this region, albeit in a more focal
pattern with prominent peaks near the transcription start site
(TSS) of each gene (Fig. 4A and Fig. S8A). The correlation be-
tween H2Bub and H3K79me2 enrichment within coding regions
was further veriﬁed using a metaanalysis of known MLL-AF9
target genes (Fig. 4 B and C). Interestingly, knocking down ex-
pression of MLL-AF9 led to reduced levels of H3K79me2 and
H2Bub at Hoxa9 without an effect on H3K4me3 (Fig. S9). These
results together suggest that H2Bub and H3K79me2 are coupled
to one another at MLL-AF9 targets.
H2Bub and H3K79me2 are coupled generically to transcrip-
tion elongation by RNA polymerase II (39, 40). Hence, it should
be noted that we found MLL-AF9 target genes to be profoundly
H3K79 hypermethylated, likely as a result of the MLL-AF9:
DOT1L interaction (Fig. S8), consistent with prior observations
(11). In contrast, we found that H2Bub was present at only
moderate levels in the body of MLL-AF9 target genes, in relative
proportion to the expression level of this set of genes (Fig. S8).
This result suggests that Rnf20 recruitment to MLL-AF9 target
genes might be mediated through an association with the elongating
form of RNA polymerase II, rather than via direct interactions
with MLL-AF9.
Rnf20 Is Required to Maintain Local H3K79 Hypermethylation at
MLL-AF9 Target Genes. Because the presence of H2Bub on nucle-
osomes is known to increase the methyltransferase activity of
DOT1L (25), we hypothesized that many of the phenotypes
described above could be explained by Rnf20 acting to maintain
H3K79 methylation in leukemia cells. We ﬁrst evaluated this on
a global level by Western blotting with histone modiﬁcation-
speciﬁc antibodies (Fig. 5A). Dox-induced Rnf20 knockdown led
to a global reduction of H2Bub; however, we found only minimal
reductions in global H3K79me2 under these conditions (Fig.
5A). Global H3K4me3 was also similarly unaffected by Rnf20
knockdown (Fig. 5A). We next considered whether Rnf20 might
instead inﬂuence the local accumulation of H3K79 methylation
in the vicinity of genes regulated by MLL-AF9. Using ChIP-
quantitative PCR (qPCR), we found that levels of H3K79me2
were decreased at the Hoxa9 andMeis1 transcribed regions upon
Rnf20 knockdown (Fig. 5C and Fig. S10A), whereas levels of this
mark were unaffected at the highly expressed splicing factor
arginine/serine rich 10 (Sfrs10) gene, which is not regulated by
MLL-AF9 (Fig. S10B). Consistent with the Western blotting
results, Rnf20 knockdown led to a decrease in H2Bub levels at
all sites examined (Fig. 5B and Fig. S10B). H3K4me3 levels were
unaffected at Hoxa9 and Sfrs10 upon Rnf20 knockdown (Figs.
S10B and S10C). These ﬁndings suggest that Rnf20 is necessary
for local Dot1l-mediated H3K79 methylation at MLL-AF9
target genes.
Discussion
The ﬁndings presented here implicate Rnf20 as a participant in
the mechanism of leukemic transformation by the MLL-AF9
oncoprotein. This is primarily supported by (i) the RNF20 re-
quirement for rapid proliferation of MLL-rearranged human
AML cell lines and for disease progression in a genetically
engineered mouse model and (ii) the similarity between gene
expression changes that occur upon RNF20 knockdown and the
known target genes of MLL-AF9 and its cofactor DOT1L. These
results lead us to propose the following model, depicted in Fig.
5D. MLL-AF9 is known to up-regulate Hoxa9 transcription, in
part, via the physical interaction between AF9 and DOT1L (9,
11). Through mechanisms that are not fully understood, DOT1L-
dependent H3K79 methylation in the vicinity of Hoxa9 leads to
increased rates of transcription by RNA polymerase II (9, 11, 13).
RNF20 is likely to be recruited to Hoxa9 by transcription elon-
gation complexes, resulting in H2Bub accumulation in the gene
body in a manner dependent on MLL-AF9–mediated transcrip-
tional activation. Prior studies have demonstrated that RNF20
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directly binds the PAF elongation complex, which could ac-
count for the observed H2Bub enrichment in the gene body of
MLL-AF9 targets (19, 21). Interestingly, MLL-fusion proteins
can also bind directly to PAF (4, 41), an interaction that may
also stabilize RNF20 recruitment to Hoxa9. As nucleosomes
containing H2Bub are better substrates for DOT1L (25), the
presence of RNF20 at Hoxa9 would trigger increased H3K79
methylation at this region. As such, the net consequence of
RNF20 recruitment would be to strengthen MLL-AF9/DOT1L–
mediated transcriptional activation through a feedforward loop
(Fig. 5D). In this model, RNF20 acts as an ampliﬁer of MLL-
AF9 function, enabling more robust H3K79 hypermethylation
and consequent increases in transcriptional activation. As a result,
leukemia cells rely on RNF20 to maintain their leukemogenic gene
expression program in a form of “nononcogene addiction” (42).
A remarkable feature of Rnf20 and Dot1l function in this
system is that inhibiting either enzyme leads to relatively selec-
tive effects on transcription of MLL-AF9 target genes, despite
H2Bub and H3K79me2 being enriched in the transcribed portion
of most active mammalian genes (11, 27, 40). One possible
explanation for this ﬁnding is that H2Bub and H3K79me2 only
promote transcription elongation in speciﬁc chromatin envi-
ronments. It is interesting to note that the HOXA cluster pos-
sesses a unique chromatin architecture: a dense arrangement of
genes in identical orientation, broad domains of histone mod-
iﬁcations (43), extensive higher order chromatin interactions
(44), and several interspersed long noncoding RNAs (45). We
speculate that this scenario, together with the aberrant activa-
tion stimulus provided by the MLL-fusion protein, creates
a situation in which cross talk between Dot1l and Rnf20
becomes critically required for productive transcription.
Our ﬁndings also implicate RNF20 as a possible therapeutic
target in the MLL-rearranged subtype of leukemia. Targeting of
other E3 ligase proteins with known drugs provides proof-of-
principle that potent small-molecule inhibitors can be de-
veloped against this class of enzymes (46, 47). However, because
E3s rely on extensive protein:protein interactions to promote
ubiquitin ligation to substrates, the ideal mode of RNF20 in-
hibition for therapeutic purposes is nonobvious at present and
will require additional genetic and biochemical experiments to
elucidate. Interestingly, overexpression of RNF20 might be
a means through which leukemia cells acquire resistance to drugs
that inhibit MLL-fusion cofactors (e.g., Dot1l and Menin inhib-
itors). In such a circumstance, an elevation of H2Bub levels could
amplify the function of residual MLL-fusion complexes. Hence,
targeting of RNF20 may have clinical utility by undermining MLL-
fusion protein function and/or by overcoming acquired re-
sistance to other agents.
Materials and Methods
MLL-AF9;NrasG12D AML Mouse Model. All murine leukemia models used here
have been described previously (31, 33). In brief, leukemias were derived by
retroviral cotransduction of embryonic day 13.5 fetal liver hematopoietic
stem and progenitor cells (HSPCs) with MSCV-MLL-AF9 and MSCV-Luciferase-
IRES-NrasG12D, followed by transplantation of infected cells into sublethally
irradiated recipient mice. The Tet-on-competent leukemia cells (RN2) were
generated by cotransduction of HSPCs with MSCV-rtTA3-IRES-MLL-AF9 and
MSCV-Luciferase-IRES-NrasG12D. The MLL-AF9-Tet-off model was generated
by cotransduction of HSPCs with pSIN-TREtight-dsRed-IRES-MLL-AF9-5XFlag
and MSCV-NrasG12D-IRES-tTA. All murine leukemia cultures were derived from
bone marrow and spleen of terminally diseased mice. All mouse experiments
included in this work were approved by The Cold Spring Harbor Animal Care
and Use Committee.
Competition Assay to Score Effects of shRNAs on Cell Proliferation/Viability. For
evaluating the impact of shRNAs on leukemia expansion, cell cultures were
retrovirally transduced with individual LMN-shRNA vectors (MSCV-miR30-
shRNA-PGKp-NeoR-IRES-GFP), followed by measurement of the GFP per-
centage at various days postinfection using a Guava Easycyte (Millipore).
The rate of GFP percentage decline over time is used to infer a defect in cell
accumulation conferred by a given shRNAs relative to the uninfected cells in
the same culture. For human leukemia cell line experiments, we used theMLS
vector (MSCV-miR30-shRNA-SV40p-GFP), which allows a higher retroviral
transduction efﬁciency in these lines. This competition assay is sensitive to an
effect on either cell cycle progression or on cell survival.
In Vivo shRNA Studies. For dox-inducible shRNA experiments in vivo, RN2
leukemia cultures were retrovirally transduced with TRPMV-Neo con-
structs (pSIN-TRE-dsRed-miR30-shRNA-PGK-Venus-IRES-NeoR) followed
by G418 selection (1 mg/mL for 6 d). Clonal lines (obtained by limiting
dilution) were then transplanted into secondary recipient animals, fol-
lowed by initiation of dox administration (in drinking water and food)
after 5–6 d. Mice were monitored thereafter by bioluminescent imaging,
quantiﬁed using Living Image Software 4.0 (IVIS Spectrum system; Caliper
LifeSciences). For bioluminescent imaging, mice were injected intraperitoneally
with D-luciferin (Gold Biotechnology).
RNA-Seq. Total RNA was extracted using TRIzol reagent (Invitrogen) according
to the manufacturer’s instruction. One microgram of total RNA was sub-
jected to “not-so-random” (NSR) primer-based RNA-seq library preparation
according to protocols described previously (48). The prepared DNA was
sequenced using an Illumina HiSEq 2000. The obtained reads were trimmed
into 28 base reads corresponding to 9th to 36th position from the 5′ ends
of the reads. These reads were mapped to the mouse genome (mm9) using
Bowtie allowing no mismatch. Gene expression was analyzed by using
Cufﬂinks software (http://cufﬂinks.cbcb.umd.edu/). Heat maps were gener-
ated with Java Tree View using a 20 reads per million per kilobase (RPKM)
expression cutoff (49). Gene set enrichment analyses were performed according
to the instructions described at www.broadinstitute.org/gsea/index.jsp (35).
ChIP-Seq. ChIP assays were performed as previously described (50). Brieﬂy, cells
were ﬁxed with 0.4% formaldehyde at room temperature for 10 min, and
chromatin was sonicated in RIPA buffer with 0.3 M NaCl to the size range of
500–100 bp. For each ChIP-seq library, around 10 ng of immunoprecipitated
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Fig. 5. Rnf20 is required for local H3K79 methylation at Hoxa9. (A) Western
blotting of acid-extracted histones prepared from RN2 cells after 4 d of dox-
induced shRNA expression using the TRMPV-Neo vector. The bottom panel
shows a Coomassie-stained SDS/PAGE gel indicating levels of the four core
histones. A twofold dilution of each sample was included to highlight the
minimal effects of Rnf20 shRNAs on H3K4me3 and H3K79me2. Repre-
sentative experiment of three independent repeats is shown. (B and C )
ChIP-qPCR evaluation with indicated antibodies following conditional Rnf20
knockdown (shRnf20.3595 was used). Different PCR amplicons are labeled
along the x-axis. Neg ctl refers to negative control primers that amplify
a nontranscribed region downstream of the Hoxa locus. Pro, Hoxa9 promoter.
“+2 kb” is relative to the Hoxa9 TSS. Control cells were not treated with
dox. Mean of three independent experiments is shown. All error bars denote
SEM. (D) Model depicting the role of Rnf20 in amplifying MLL-AF9–mediated
transcriptional activation through cross talk with Dot1l.
Wang et al. PNAS | March 5, 2013 | vol. 110 | no. 10 | 3905
CE
LL
BI
O
LO
G
Y
DNA was used for library construction. After end repair and addition of “A”
base to 3′ ends, barcoded adaptors were ligated to DNA fragments. Fol-
lowing a 17-cycle PCR, libraries were puriﬁed by two rounds of Ampure XP
beads (Beckman Coulter; A63881) puriﬁcation and one step of agarose gel
puriﬁcation. ChIP-seq libraries were sequenced on HiSEq 2000 (50 bp, single
end). Reads were mapped to human genome (hg19) using BWA (http://bio-
bwa.sourceforge.net/). Data were visualized at representative loci using the
Integrative Genomics Viewer (www.broadinstitute.org/igv/). To examine the
levels of histone modiﬁcations in speciﬁc gene groups, we separated the
genes into four groups according to their expression. We ranked the genes
according to their RPKM values from low to high, using RNA-seq data
obtained from THP-1 cells. Genes with 0 RPKM were deﬁned as the silent
genes (6,221 genes). The remaining genes were then divided into three
roughly equal-sized groups of 5,000 genes: low, medium, and high. See
SI Materials and Methods for details of experimental methods for tissue
culture and for sequences of all primers and shRNAs used here.
Histone Extraction and Western Blotting. Cells were washed with PBS and lysed
with buffer A solution (10 mM Hepes·KOH, pH 7.9, 15 mM MgCl2, 10 mM
KCl). Cell pellets were resuspended in 0.2 N HCl. Supernatant was isolated
followed by the addition of trichloroacetic acid (Sigma; T6399). Precipitate
was carefully washed with acetone and resuspended in deionized water
and run on an SDS/PAGE gel. For Rnf20 Western blot, ∼50,000 cells were
lysed directly into Laemmli buffer and resolved using SDS/PAGE electro-
phoresis, followed by transfer to nitrocellulose for blotting.
Antibodies. Anti–β-actin HRP (Sigma; A3854), anti-Rnf20 antibody (Novus
Biological; NB100-2242), anti-H3K4me3 (Millipore; 07-473), anti-H3K79me2
(Abcam; ab3594), anti-H2Bub (Millipore; 05-1312), and anti-H3 (Abcam; ab1791).
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